BiotechTube
Home/KAHR Medical/Prof. Yael Ben‑Ari
PY

Prof. Yael Ben‑Ari

CSO

KAHR Medical

Therapeutic Areas

Genetic DisordersOncology

KAHR Medical Pipeline

DrugIndicationPhase
KHR‑001Duchenne Muscular DystrophyPreclinical
KHR‑002Cystic FibrosisPreclinical
KHR‑003Solid Tumor Immuno‑OncologyPreclinical

Leadership Team at KAHR Medical

DE
Dr. Eli Cohen
CEO
DL
David Levi
COO
View full KAHR Medical profile